DIRS.INFO The most relevant business & tech news

☆ Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
▼ + stars: | 2024-05-03 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Read previewDanish drugmaker Novo Nordisk will lower prices of its weight loss drug Wegovy as it plans to raise sales volumes and navigate tough competition. Prices for the blockbuster drug fell in the first quarter. Sales of Wegovy more than doubled in the first quarter year-on-year, to 9.4 billion Danish crowns, or $1.3 billion, according to the company's earnings. They did not specify how much Novo plans to cut Wegovy's prices. AdvertisementThe Danish pharmaceutical maker, which also produces viral weight loss drug Ozempic, reported better-than-expected sales of 65 billion Danish crowns, or $9.4 billion, in the first quarter.

Persons: —, Karsten Munk Knudsen, Knudsen, Lars Fruergaard Jorgensen, Ozempic, Eli Lilly, Wegovy, Bernie Sanders, Goldman Sachs, Oprah Winfrey, Elon Musk, Charles Barkley Organizations: Service, Nordisk, Business Locations: Danish, Novo

☆ Wegovy maker Novo Nordisk down 4%, heads for worst day since October
▼ + stars: | 2024-05-03 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% loss on Thursday as analysts pored over the details of the firm's first-quarter results and monitored a potential rival weight loss treatment. The company reported that sales for its blockbuster injectable weight loss treatment Wegovy, more than doubled to 9.38 billion Danish kroner ($1.4 billion). Novo Nordisk, which also makes diabetes treatment Ozempic, said the rise in sales had offset a slight reduction in prices. Analysts expected even higher weight loss drug sales in the quarter, and some noted that Novo Nordisk's 2024 outlook raise for both sales growth and operating profit was due to one-off accounting adjustments. The boom in demand for weight loss treatments saw Novo Nordisk overtake French luxury group LVMH to become Europe's most valuable company last year.

Persons: Karsten Knudsen, Karen Andersen Organizations: Novo Nordisk, Novo, Morningstar Locations: Novo

☆ GNC is redesigning stores to draw people taking Ozempic
▼ + stars: | 2024-04-29 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +3 min

The brand hopes a new strategy tailored to people taking GLP-1 drugs for weight loss will help draw customers into stores and grow its business. We can help,” advertises an overhead banner in GNC’s new GLP-1 “support section.”GNC's new GLP-1 support section is available in all 2,300 stores across the United States. JON SIMON/GNCDanish pharmaceutical company Novo Nordisk is reaping huge profits from creating and selling the hit GLP-1 products. JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population. GNC, which filed for bankruptcy in 2020 and closed more than 1,200 stores, is the latest brand to build a strategy around people taking GLP-1s.

Persons: New York CNN — GNC, GNC, ”, JON SIMON, WeightWatchers Organizations: New, New York CNN, Novo Nordisk, Pfizer, Roche, JPMorgan, Equinox Locations: New York, United States, Danish

☆ Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
▼ + stars: | 2024-03-17 | by ( George Glover | ) www.businessinsider.com time to read: +2 min

Danish pharma giant Novo Nordisk makes both Ozempic and Wegovy. The novel drugs are also boosting pharma stocks — and Denmark's economy. Advertisement"The pharmaceutical industry has been the main driving force in the Danish economy in both the fourth quarter and for the whole of 2023," the agency said. Genmab, Zealand Pharma, and H. Lundbeck are among the other big Danish pharma firms. AdvertisementSuch businesses were a rare bright spot for Denmark's economy last year because they invested in infrastructure, created jobs, and boosted manufacturing, according to Danske Bank's chief economist Las Olsen.

Persons: —, it's, Las Olsen, Olsen Organizations: Danish pharma, Novo Nordisk, Service, Nordisk, Zealand Pharma Locations: Denmark, Danish, Copenhagen

☆ Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
▼ + stars: | 2024-03-08 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Liselotte Sabroe | AFP | Getty ImagesWegovy obesity drug maker Novo Nordisk surpassed Tesla in market value, after fresh early trial data showed positive results for its new experimental weight loss pill. Novo Nordisk is now the 12th most valuable company in the world, with a market cap of $604 billion — ahead of Tesla's $569 billion, according to FactSet data. 8The uptick of Thursday extends a months-long rally for Novo Nordisk, as excitement grows around weight loss drugs and their potential wider applications. The early amycretin data marks a fresh milestone for Novo Nordisk, potentially offering a more effective and less intrusive alternative to its already widely successful injection-based Wegovy and Ozempic drugs. Wegovy showed weight loss of 6% in a 12-week trial, while Ozempic is a diabetes treatment.

Persons: Liselotte Sabroe, Eli Lilly, amycretin, Martin Holst Lange, Lange Organizations: AFP, Getty, Novo Nordisk, Tesla, Microsoft Corp MSFT, Apple Inc, AAPL, NVIDIA Corp NVDA Technology, Saudi Aramco, SA Energy, Inc, AMZN Consumer, GOOGL, Berkshire Hathaway BRK.B, Company LLY Healthcare, Broadcom Inc, AVGO Technology, Taiwan Semiconductor TSM, Novo Nordisk NVO, Finance, JPMorgan Chase JPM, Reuters Locations: Bagsvaerd, Copenhagen, Denmark, Danish, London, Saudi, Mar, Europe

☆ Stocks making the biggest moves premarket: Novo Nordisk, New York Community Bancorp, Victoria's Secret, Nvidia and more
▼ + stars: | 2024-03-07 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Nvidia — Semiconductor companies rose broadly as a group, with the VanEck Semiconductor ETF gaining 1.5% in the premarket. Intel shares rose 1.7%. Kroger — Shares rose 6% after the supermarket chain reported fourth-quarter better-than-expected earnings. Analysts expected a profit of 50 cents per share on revenue of $1.67 billion, according to LSEG. Victoria's Secret expects $6 billion full-year revenue, less than the $6.2 billion expected from analysts polled by FactSet.

Persons: Eli Lilly, Mizuho, LSEG, Tesla, NYCB, — CNBC's Michelle Fox, Hakyung Kim, Jesse Pound, Pia Singh Organizations: Nordisk —, Nvidia — Semiconductor, VanEck Semiconductor, Nvidia, Micron Technology, Stifel, Broadcom, Intel, Kroger, Eagle Outfitters, Citi, York Community Bancorp, FactSet, York Community Locations: Danish, American

Even as countries around the world have stepped in to require lower priced drugs for their citizens, the United States has been reticent to do so. As a result, U.S. consumers pay the highest prices in the world for drugs, by a wide margin. But the impetus for more fundamental reform may come from an unexpected place: America’s obesity epidemic. Many of us are aware that there is a new class of weight-loss drugs that offer enormous promise in addressing obesity. But there is far less awareness of the fact that these drugs also introduce an enormous risk to America’s taxpayers.

Organizations: pharma, Novo Nordisk, Ozempic Locations: United States, U.S, Danish

☆ Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars
▼ + stars: | 2024-01-31 | by ( Elliot Smith | ) www.cnbc.com time to read: 1 min

Novo Nordisk, Europe's largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar. The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates (CER) to 232.3 billion kroner ($33.71 billion). Full-year operating profit jumped by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner. The Danish pharmaceutical giant said it expects sales growth this year of between 18% and 26% in CER terms, as demand surges for Wegovy and Ozempic, which contain the same active ingredient. The 2023 results were fueled by strong performance in the company's diabetes and obesity care division, with obesity care in particular spiking by 154% at CER to 41.6 billion.

Persons: Ozempic Organizations: Novo Nordisk Locations: Europe's, Danish, CER

STAVANGER (AP) — Norway’s oil fund reported the largest annual return in its history Tuesday, a performance led by U.S. technology companies and Danish pharmaceutical company Novo Nordisk, which makes the diabetes-turned-weight loss drug Ozempic. Norway’s Government Pension Fund Global, the world’s largest sovereign wealth fund, said it also benefited in 2023 from market excitement over the rapid adoption of artificial intelligence technology such as ChatGPT. The six largest contributors to the fund’s growth were the U.S technology companies Microsoft, Apple, NVIDIA, Meta, Amazon and Alphabet. Nova Nordisk also makes a higher dose version of the same medication that is sold as a weight loss drug under the brand name Wegovy. Political Cartoons View All 253 ImagesThe Government Pension Fund Global, known commonly as the Oil Fund, invests Norway's profits from oil and gas, and owns around 1.5% of all the companies listed globally.

Persons: Nicolai Tangen, Tesla, Ozempic Organizations: STAVANGER, Novo Nordisk, Fund, Oil, Microsoft, Apple, NVIDIA, Meta, Nova Nordisk, Nordisk, Government Pension Fund, Oil Fund Locations: U.S, Danish, Norway’s, Norway, Denmark

☆ LVMH shares jump 8% as earnings point to luxury sector resilience
▼ + stars: | 2024-01-26 | by ( Elliot Smith | ) www.cnbc.com time to read: +3 min

Bernard Arnault, Chairman and CEO of LVMH Moet Hennessy Louis Vuitton, speaks during a press conference to present the 2023 annual results of LVMH in Paris, France, January 25, 2024. LVMH shares jumped more than 8% on Friday morning, after the world's largest luxury group posted higher-than-expected sales for 2023 and raised its annual dividend. The result was boosted in particular by 14% annual growth in the critical fashion and leather goods sector, along with 11% growth in perfumes and cosmetics. After a boom during the pandemic, the luxury sector endured a rough end to 2023 as challenging geopolitical and macroeconomic conditions weighed on consumer spending, particularly in the U.S. and China. Javier Gonzalez Lastra, portfolio manager of the Tema Luxury ETF, told CNBC on Thursday that investors are trying to gauge where the bottom of the earnings cycle revision is for the luxury sector.

Persons: Bernard Arnault, LVMH Moet Hennessy Louis Vuitton, LVMH, Louis Vuitton, Hennessy, Bulgari, Javier Gonzalez Lastra Organizations: LVMH, Chandon, Givenchy, Novo Nordisk, Burberry, CNBC, Paris Locations: Paris, France, U.S, China, LVMH, Tema

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

☆ Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France
▼ + stars: | 2023-11-23 | by ( ) www.reuters.com time to read: +1 min

The logo of Danish drugmaker Novo Nordisk in their offices in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little Acquire Licensing RightsPARIS, Nov 23 (Reuters) - French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk (NOVOb.CO) in France, his office said, pitching it as a sign of newly restored French industrial competitiveness. The investment, for which no detail was provided by Macron's office, will be based in Chartres, west of Paris, where Novo already employs nearly 2,000 people. The Elysee palace deemed it the most significant investment in the health sector of Macron's mandates so far and said it would create 500 jobs. ($1 = 0.9168 euros)Reporting by Michel Rose, Editing by Dominique VidalonOur Standards: The Thomson Reuters Trust Principles.

Persons: Tom Little, Emmanuel Macron, Michel Rose, Dominique Vidalon Organizations: Novo Nordisk, REUTERS, Rights, Thomson Locations: Danish, Hillerod, Denmark, France, Chartres, Paris

☆ Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
▼ + stars: | 2023-11-11 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Novo Nordisk's Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on heart attacks, a promising new frontier for the drug. The roughly 17,500-person Select study tested Wegovy in people with obesity and heart disease but who did not have diabetes. The new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week. Zepbound has been shown to help people lose more weight, but it hasn't yet demonstrated an effect on cardiovascular outcomes.

Persons: Robert Kushner, Eli Lilly, Zepbound, Howard Weintraub Organizations: Wegovy, American Heart Association Scientific Sessions, New England, of Medicine, Novo Nordisk, Northwestern University Feinberg School of Medicine, Center for, NYU Langone Locations: Danish, U.S

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Novo Nordisk on Thursday reported record profits and sales for the third quarter, but said supplies of its hugely popular weight loss drug Wegovy would continue to be restricted. The Danish pharmaceutical giant posted third-quarter sales of 58.73 billion Danish krone ($8.34 billion), a 29% increase from the same period last year, driven by demand for its flagship Ozempic and Wegovy drugs in the U.S. The company has struggled to keep up with demand for Wegovy, an appetite-suppressing anti-obesity drug, forcing it to limit the number of patients able to begin treatment.

Persons: Wegovy, Elliot Smith Organizations: Novo Nordisk, U.S Locations: Danish

☆ Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
▼ + stars: | 2023-11-02 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Michael Siluk | UCG | Getty ImagesNovo Nordisk said Thursday that its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months. "I would say from today, [the outcome will be] less than six months," Knudsen told CNBC's Julianna Tatelbaum on "Street Signs." watch nowEarlier Thursday, Novo Nordisk in its third-quarter earnings announced plans to get expanded approval from the FDA, but shared no timeline. "The SELECT study is, in an obese population with established cardiovascular disease, does Wegovy reduce cardiovascular risk?

Persons: Michael Siluk, Karsten Munk Knudsen, Knudsen, CNBC's Julianna Tatelbaum, " Knudsen, Novo Organizations: UCG, Getty, Novo Nordisk, U.S . Food, Drug Administration, CNBC, FDA, Novo Nordisk's Locations: U.S, Danish

☆ Here's why Jim Cramer likes J.M. Smucker's plan to buy the maker of Twinkies
▼ + stars: | 2023-09-11 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +1 min

Smucker 's (SJM) decision to buy Twinkie maker Hostess Brands (TWNK) in a deal valued at $5.6 billion. "I like the deal, if only just because I like this channel for Smuckers," Cramer said on "Squawk on the Street." Hostess Brands stock, meanwhile, surged nearly 19%, to more than $33 per share. Reuters reported in August that multiple major food brands such as General Mills (GIS) and Oreo owner Mondelez International (MDLZ) had shown interest in acquiring Hostess. Perhaps the "biggest worry" about acquiring Hostess Brands is the increasing popularity of weight-loss drugs known as GLP-1 agonists, and their potential impact on consumer food preferences, Cramer acknowledged.

Persons: CNBC's Jim Cramer, J.M, Smucker, Cramer, Jim Cramer's, Mills, Morgan Stanley, Eli Lilly, — Organizations: Hostess Brands, Reuters, Mondelez, Hostess, Cramer's Charitable Trust, CNBC, Novo Nordisk, Cramer's Charitable Locations: U.S

☆ Blockbuster weight loss drugs Wegovy and Ozempic are being tested to treat addiction and dementia
▼ + stars: | 2023-09-07 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +6 min

Weight loss drugs are being assessed for their ability to treat conditions like dementia and addiction after a landmark study showed that Wegovy helped reduce the risk of heart attacks and strokes. Late-stage trial data released last month by Novo Nordisk indicated that its Wegovy weight loss injection led to "large reductions" in heart failure-related symptoms among at-risk patients. A treatment for drug and alcohol abuseHendershot is one researcher investigating whether the appetite-regulating mechanisms at play in weight loss drugs could be used to treat other conditions such as alcohol and drug addiction. Novo Nordisk's Wegovy and Eli Lilly 's Mounjaro work by imitating a naturally occurring gut hormone that helps regulate appetite in the brain, ultimately leading to weight loss. Implications for reward signalingAdditional possible use cases for weight loss drugs could exacerbate the hurdles already faced by patients using them, however: high costs and supply shortages.

Persons: Wegovy, —, Hendershot, Nordisk's Wegovy, Eli Lilly, Kyle Simmons, Simmons, Ivan Koychev, Harshal Deshmukh Organizations: Bloomberg, Getty, Novo Nordisk, University of North, Chapel Hill, CNBC, Nordisk's, Oklahoma State, Oklahoma State University, University of Baltimore, University of Oxford, University of Hull Locations: Danish, University of North Carolina, Chapel

☆ Business is booming for the maker of weight-loss drugs Wegovy and Ozempic — so much so that it is threatening luxury giant LVMH's crown as Europe's most valuable firm
▼ + stars: | 2023-09-05 | by ( Grace Dean | ) www.businessinsider.com time to read: +3 min

Novo Nordisk has been trading places with LVMH for the title of Europe's most valuable company. The Danish pharmaceutical giant makes the buzzy weight-loss drugs Wegovy and Ozempic. AdvertisementAdvertisementNovo Nordisk, the maker of weight-loss drug Wegovy and diabetes drug Ozempic, has been trading places with French luxury-goods conglomerate LVMH for the title of now Europe's most valuable firm. The UK's NHS recently said that it plans to begin giving out some limited supplies of Wegovy for weight management. Arnault and his family own around 48% of the company's total shares.

Persons: Wegovy, Louis Vuitton, Ozempic, Elon Musk, Bernard Arnault, Arnault Organizations: Novo Nordisk, Morning, Nordisk, Dior, Tiffany, FDA, NHS Locations: LVMH, Danish, GLP, North America

☆ Inside the struggles at Calibrate, a new kind of weight-loss startup that's facing a mountain of patient complaints and refunds
▼ + stars: | 2023-09-05 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +19 min

Weight-loss startup Calibrate has struggled to get patients access to buzzy drugs like Ozempic. Kenyon's startup Calibrate, which she launched in June 2020, is one of the healthcare companies feeding the frenzy. CalibrateThe company is now running up against several massive challenges: Weight-loss drugs are expensive and in short supply, and health insurers are increasingly reluctant to pay for them. Kenyon said about 20% of Calibrate members do not have coverage for weight-loss medications, and around half of those people request refunds from Calibrate. Want to tell us about your experience with Calibrate or weight-loss drugs?

Persons: lightbulb, Isabelle Kenyon, Kenyon, Jenny Craig, OptumRx, She's, she's, Saxenda, —, weren't, It's, they've, Holly, hadn't, hasn't, Claire Rosenzweig, Rosenzweig, it's, Andrew Kelly, Shelby Livingston, Rebecca Torrence Organizations: New, Tiger Global, Founders Fund, Optum Ventures, FedEx, Food and Drug Administration, Jefferies, Better Business Bureau, BBB, Better Business, Metropolitan New, Better, Apple, Businessolver, Optum, UnitedHealth, Employees, REUTERS, Madryn Asset Management, SM Ventures, Ventures Locations: America, New York, Danish, GLP, Florida, Metropolitan New York, slivingston@insider.com, rtorrence@insider.com

☆ Novo Nordisk's Wegovy weight loss drug launches in the UK
▼ + stars: | 2023-09-04 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Novo Nordisk launched its Wegovy weight loss injection in the U.K. on Monday, advancing the drug's rollout in Europe despite ongoing supply constraints. The drug will also be available privately through a "registered healthcare professional," Novo Nordisk said in a statement, without adding further detail. Novo Nordisk declined to disclose the final price agreed with NHS England for the drug, but said that NICE, the U.K. drug cost-effectiveness watchdog, had described it as a "cost-effective use of NHS resources." British insurance company Aviva , which provides private health insurance to around 1.1 million Brits, on Monday said that Wegovy would not be covered under its policy, according to Reuters.

Persons: Wegovy Organizations: Novo Nordisk, National Health Service, National Institute for Care, Nordisk, England, NICE, Aviva, Reuters Locations: Danish, Europe, U.S

☆ Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soar
▼ + stars: | 2023-08-10 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +1 min

A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. The company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy. Novo Nordisk , which makes the weight-loss drug Wegovy, raised its outlook for 2023 Thursday, as it reported soaring sales. For 2023, the company now anticipates sales growth of 27%-33% and operating profit growth of 31%-37%, at constant exchange rates. The active ingredient in Wegovy is semaglutide, an FDA-approved drug that works by imitating a naturally-occurring gut hormone that helps to regulate appetite.

Persons: Wegovy, Lars Fruergaard Jørgensen, — Sam Meredith Organizations: Novo Nordisk, FDA Locations: Chicago , Illinois, U.S, Danish

☆ European markets climb with inflation, Italian banks in focus
▼ + stars: | 2023-08-09 | by ( Elliot Smith | ) www.cnbc.com time to read: +2 min

LONDON — European markets advanced on Wednesday, as traders digested China's disinflation and Italy's weakening of a surprise windfall tax on banks. The European blue chip index closed the Tuesday session 0.2% lower, with banks shedding 2.7% after the Italian government announced a surprise windfall tax on excess profits. Shares of Italian banks took a tumble on Tuesday as a result of a tax on net interest income announced on Monday. Citi analysts estimated that the levy represent around 19% of Italian lenders' net profits for the year. A Reuters poll of economists produced a consensus forecast for the July print of 3.3% year-on-year, up from 3% in June.

Persons: Hong Kong, Moody's Organizations: Novo Nordisk, Monday, Citi, Global, U.S, CPI, Federal, ABN Amro, TUI Locations: Stocks, China, Hong, Europe

☆ Obesity drug Wegovy's landmark trial result could 'open up' health insurance access, analyst says
▼ + stars: | 2023-08-09 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +6 min

Until now, some health insurers have been reluctant to cover the drug, given its high costs and a lack of data around its underlying health benefits. But the results of the latest trial data could change that. "Do I think most payers will adopt [obesity drugs] overnight because of the SELECT trial? According to the World Health Organization, global obesity rates have almost tripled over the past decade. Novo Nordisk shares soared by 17% following the release of the trial results on Tuesday.

Persons: Jim Vondruska, Peter Verdult, CNBC's, Wegovy, Verdult, Martin Holst Lange, Eli Lilly, Mounjaro, Michael Mason, Eli Lily, Lilly Diabetes, It's, Lilly, Novo, Lily Organizations: Reuters LONDON, Novo Nordisk, Citi, Novo, World Health Organization, Barclays, Citi Verdult, European Markets Authority Locations: Chicago , Illinois, Danish, U.S, Europe, London

☆ Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
▼ + stars: | 2023-08-08 | by ( Sam Meredith | ) www.cnbc.com time to read: +2 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Shares of Danish drugmaker Novo Nordisk soared on Tuesday, after late-stage trial data showed that its obesity drug Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%, compared with a placebo. Shares of Novo Nordisk rose nearly 16% during mid-morning deals, before paring gains. Martin Holst Lange, executive vice president for development at Novo Nordisk, said that the results showed that the company's obesity drug "has the potential to change how obesity is regarded and treated." "Therefore, we are very excited about the results from SELECT showing that semaglutide 2.4 mg reduces the risk of cardiovascular events."

Persons: Martin Holst Lange, Holst Lange Organizations: Novo Nordisk, Nordisk, Investors, Reuters Locations: Danish, semaglutide

☆ Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
▼ + stars: | 2023-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +3 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.

Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S

Search resuls for: "Danish pharma"

25 mentions found